Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Titel:
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Auteur:
Ferris, R.L. Haddad, R. Even, C. Tahara, M. Dvorkin, M. Ciuleanu, T.E. Clement, P.M. Mesia, R. Kutukova, S. Zholudeva, L. Daste, A. Caballero-Daroqui, J. Keam, B. Vynnychenko, I. Lafond, C. Shetty, J. Mann, H. Fan, J. Wildsmith, S. Morsli, N. Fayette, J. Licitra, L.